01/03/2008
Kapadia M. R.; Chow L. W.; Tsihlis N. D; Ahanchi S. S.; Eng J. W.; Murar J.; Martinez J.; Popowich D. A.; Jiang Q.; Hrabie J. A.; Saavedra J. E.; Keefer L. K.; Hulvat J. F.; Stupp S. I.; Kibbe M. R. “Nitric oxide and Nanotechnology: A Novel Approach to Inhibit Neointimal Hyperplasia” Journal of Vascular Surgery, 47(1), (2008) 173-182.
Nitric oxide (NO) has been shown to inhibit neointimal hyperplasia after arterial interventions in several animal models. To date, however, NO-based therapies have not been used in the clinical arena. Our objective was to combine nanofiber delivery vehicles with NO chemistry to create a novel, more potent NO-releasing therapy that can be used clinically. Thus, the aim of this study was to evaluate the perivascular application of spontaneously self-assembling NO-releasing nanofiber gels. Our hypothesis was that this application would prevent neointimal hyperplasia.
Perivascular application of NO-releasing self-assembling nanofiber gels is an effective and simple therapy to prevent neointimal hyperplasia after arterial injury. Our study demonstrates that the PROLI/NO nanofiber gel most effectively prevented neointimal hyperplasia and resulted in less inflammation than the DPTA/NO nanofiber gel. This therapy has great clinical potential to prevent neointimal hyperplasia after open vascular interventions in patients.